Reeve Emma 4

What Happened

• Emma Reeve, a director of Whitehawk Therapeutics, was granted a derivative equity award covering 38,040 shares on June 12, 2026. The award shows an acquisition price of $0.00 (i.e., no cash paid at grant).
• This is an award/grant (compensation) rather than an open-market purchase or sale; the award is subject to vesting conditions described below.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026.
• Transaction type: Award/Grant (derivative security), 38,040 shares, acquisition price $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Vesting footnote: 100% of the shares subject to the award vest on the earlier of (i) the one-year anniversary of the Date of Grant (June 12, 2027) or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant, provided Reeve continues as a service provider under the 2021 Equity Incentive Plan.
• No indication in the filing that the award was immediately exercisable or that any shares were sold; this is a compensation grant, not a sale or open-market buy.

Context

• Grants like this are typically part of director compensation and reflect incentives to retain service rather than an immediate market bet. Because vesting is conditioned on continued service and the grant price is $0, the economic benefit accrues only if vesting conditions are met.
• The filing was submitted three days after the reported transaction; the Form 4 shows the transaction date and the filing date but does not indicate any exception or notation of lateness in the document summary.